Exelixis is an overlooked stock with a proven cancer franchise, particularly its successful drug cabozantinib, offering strong commercial performance in the attractive oncology sector.
Source Post
3 Under-the-Radar Stocks That Could Change Investors Lives
Jul 11, 2026
This video highlights three under-the-radar stocks with significant long-term potential. The first stock discussed is Axsome Therapeutics (AXSM), a biotechnology company focused on neurological disorders. The creator emphasizes its strong revenue growth, particularly from its flagship product Auvelity, and its recent label expansion for Alzheimer's disease agitation, highlighting the large unmet need and efficient commercial strategy.
Linked Mentions
Tickers discussed in this post
Madrigal Pharmaceuticals (MDGL) is a first-mover in treating MASH, a progressive liver disease, with its newly approved therapy Rezdiffra, addressing a large unmet medical need and potentially creating a lasting advantage.
Axsome Therapeutics (AXSM) is a promising biotech stock with strong revenue growth from Auvelity and a significant opportunity in Alzheimer's disease agitation.